abstract KEYWORD INDEX 358 antigen-presenting cells 851, 867 anti-HMGB1 abtibodies 1195 antihypertensives 958 anti-IL-1 therapy 1375 anti-Jo-1 926 anti-lymphocyte antibodies 749 antimalarial drugs 459, 1879 antimalarials 445 anti-MCV 660 anti-MDA5 antibody 1672 anti-melanoma differentiation–associated gene 5 antibody 916 anti-mullerian hormone 1145 anti-mutated citrullinated vimentin 1741 anti-N-methyl-D-aspartate receptor antibody 1844 anti-NMO IgG 1174 antinuclear antibodies (ANA) 210, 911, 913, 1188, 1341, 1845, 1871, 2197 antioxidants 1510 anti-phosphatidylserine/prothrombin 14 antiphospholipid antibodies 1360, 1361 antiphospholipid syndrome 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 621, 1160, 1356, 1357, 1358, 1359, 1360, 1692, 2251, 2253, 2254 antiprothombin antibodies 12 anti-prothrombin/phosphatidylserine antibodies 12 anti-Ro antibodies 489 anti-Ro/SSA antibodies 1142 anti-SRP 915 antisynthetase syndrom 917 antithrombin 8 anti-TNF 849, 1804 anti-TNF therapy 56, 76, 90, 139, 239, 290, 291, 297, 305, 309, 329, 330, 338, 344, 371, 374, 376, 377, 385, 386, 387, 393, 402, 405, 408, 409, 415, 420, 421, 516, 538, 539, 548, 640, 698, 699, 718, 753, 756, 758, 767, 768, 782, 904, 908, 1032, 1054, 1059, 1097, 1099, 1104, 1105, 1114, 1127, 1136, 1375, 1381, 1391, 1445, 1517, 1541, 1542, 1631, 1792, 1794, 1811, 1812, 1813, 1814, 1815, 1818, 1825, 1827, 1835, 1838, 1929, 1941, 1943, 1948, 1960, 1970, 2078, 2084, 2103, 2135, 2204, 2207, 2236, 2264, 2269, 2271, 2272 anti-topoisomeras I antibodies 2214 anti-U1RNP autoantibodies 893 anti-viral prophylaxis 387 aortitis 2040 AP-1 616 AP-1 inhibitor 280, 1467 apheresis 469 apoER2 1360 apoptosis 106, 249, 368, 372, 439, 486, 489, 490, 491, 498, 694, 736, 853, 859, 965, 1079, 1135, 1195, 1214, 1260, 1478, 1516, 2121, 2174 2010 Program Book apoptotic bodies 694 appointment attendance 776, 1553 appointment reminders 1007 APRIL 1732 aquaporin 1895 arbovirus 1640, 1642 aromatase inhibitor 898, 912 arterial stiffness 375, 1839 arteriosclerosis 448, 461, 1148, 1839, 1877, 2120, 2121, 2122, 2165, 2166 arteriovenous anastomoses 1220 arthralgia 898 arthralgia syndrome 912 arthritis 691, 786, 1447 arthritis self management program 2062 arthritis symptoms 688 arthrocentesis 1431 arthropathy 886 arthroplasty 168, 178, 1080, 1385, 2059, 2061, 2137 arthroscopy 885, 1095 ASAS 552 ASAS criteria 544 ASC 2151 ASDAS 1927, 1938 aspirin 2123 assessment 7, 94, 402, 813, 905, 1291, 1344, 1431, 1623, 1747, 1754, 1840, 1857, 2031, 2063, 2109, 2110 assistive devices 169 association 833 association studies 1578 association study 824, 1974 asymptomatic 1614 atherosclerosis 430, 438, 448, 455, 471, 519, 531, 594, 637, 719, 865, 1017, 1023, 1028, 1058, 1072, 1189, 1194, 1224, 1378, 1667, 1677, 1846, 1877, 2049, 2117, 2124, 2125, 2162, 2241, 2259, 2260 attrition 2064 atypical fracture 1573 audiogram 899, 900 augmentation index 534, 1028 autoantibodies 24, 28, 77, 428, 433, 439, 486, 487, 499, 510, 575, 652, 656, 702, 715, 734, 742, 743, 748, 749, 753, 857, 892, 894, 925, 929, 934, 988, 1068, 1091, 1146, 1164, 1188, 1226, 1231, 1250, 1258, 1264, 1272, 1448, 1639, 1672, 1732, 1757, 1780, 1847, 1870, 1871, 1885, 1901, 2001, 2003, 2008, 2189, 2231, 2243 autoantibody phenotype 1678 autoantibody-inducing CD4 T cells 1258 autoantibody-inducing CD4+ T cell 867 autoantigens 350, 439, 487, 734, 1374, 2175, 2176 autoimmune arthritis 2130 autoimmune diseases 264, 287, 439, 500, 700, 715, 737, 758, 780, 792, 843, 895, 920, 927, 962, 1002, 1048, 1107, 1161, 1188, 1225, 1229, 1244, 1249, 1250, 1258, 1264, 1265, 1266, 1350, 1435, 1499, 1525, 1649, 1883, 1885, 1889, 1898, 1900, 1901, 2043, 2128, 2129, 2160, 2176, 2177, 2217, 2234 autoimmune hepatitis 892 autoimmune infiltrates 1897 autoimmune pancreatitis 1671 autoimmune thyroid disease 1038 autoinflammatory 2105 autoinflammatory disease 260, 657, 1656, 1706 autoinflammatory syndromes 1685 automated 118 automatic neuropyschologic assessment metrics 1854 autonomic disorders 626, 809, 1025, 1902 autonomic nervous system 808 autophagy 965 Avise PG 302 axial spondyloarthritis 544, 666 ayurveda 1106 azathioprine 1398, 1401, 1453, 2085 B B CD20 lymphocytes 1810 B cell activation markers 1911 B cell depleting 1802 B cell depleting therapy 741 B cell depletion 436 B cell modulation 751 B cell monoclonal proliferation markers 1911 B cell tolerance 425 B cells 15, 286, 333, 349, 355, 367, 424, 425, 608, 623, 712, 715, 730, 733, 734, 736, 737, 738, 739, 740, 741, 743, 744, 745, 746, 748, 749, 750, 751, 752, 753, 825, 1085, 1088, 1126, 1141, 1146, 1154, 1192, 1295, 1350, 1389, 1410, 1411, 1412, 1413, 1415, 1589, 1710, 1731, 1790, 1801, 1886, 1889, 1890, 1892, 1906, 1917, 1977, 2178, 2187, 2189, 2274 B7RP-1 1141 back pain 172, 175, 869, 971, 1383, 1458, 1459, 1575, 2180 bacterial infections 2015 BAFF 15, 24, 741, 926, 1126, 1379, 1389, 1413, 1890, 1892, 1998, 2129, 2177, 2187 Barrett’s esophagus 580 BASDAI 212, 534 BASDI 1925 BAX gene expression 1214 B-cell 1833, 1998 Bcl-2 family 859 BCX4208 150 Behçet’s disease 822, 839, 1249, 1281, 1285, 1289, 1293, 1297, 1305, 1308, 1307, 2200, 2217
Behcet’s syndrome 1284, 1288, 1298, 1303, 1312, 1697 belimumab 451, 452, 457, 1146, 1172, 1454, 1456, 1457, 1848 benzbromarone 2088 beta2-glycoprotein I 656 beta2-glycoprotein I receptors 1356 bias 1132 BILAG 453, 1452, 1456 Bim 859 bioactivity 282 biologic agents 758 biologic response modifiers 74, 76, 237, 300, 322, 326, 385, 386, 407, 415, 419, 420, 454, 514, 720, 890, 908, 1012, 1097, 1114, 1127, 1136, 1542, 1648, 1714, 1795, 1799, 1804, 1814, 1818, 1835, 1927, 1937, 1943, 1982, 2264, 2267 biologicals 891 biologics 68, 88, 981, 1041, 1110, 1824, 1932 biologics registries 1111, 1112 bioluminescence 1622 biomarkers 25, 49, 103, 134, 217, 245, 268, 363, 443, 506, 541, 588, 590, 711, 724, 725, 733, 808, 811, 835, 845, 861, 924, 927, 951, 979, 1098, 1146, 1147, 1175, 1190, 1218, 1230, 1379, 1399, 1403, 1451, 1466, 1491, 1496, 1601, 1606, 1608, 1740, 1751, 1753, 1764, 1782, 1784, 1804, 1886, 1890, 1899, 1904, 1908, 1911, 1918, 1953, 1968, 1985, 2012, 2047, 2049, 2106, 2116, 2149, 2161, 2265 biomechanical testing 169, 1327, 1328, 2056, 2099, 2101, 2134 biomechanics 195 BiP 1376, 1729 Birmingham vasculitis activity score (BVAS) 2035 birth cohort 2067 bisphosphonates 31, 970, 981, 994, 1005, 1372, 1543, 1561, 1665, 2089, 2213 bladder cancer 2026 blastomycosis 1643 Blau syndrome 1656, 1713 bleomycin 622 blood brain barrier 1191 BLyS 451, 452, 457, 1172, 1186, 1454, 1456, 1457, 1848 body composition 1018, 1065 body image dissatisfaction 1234 body mass 95, 173, 183, 222, 231, 515, 774, 1018, 1065, 1696 body mass index 523 bone density 121, 176, 188, 195, 206, 222, 798, 958, 959, 960, 974, 979, 982, 1156, 1206, 1317, 1546, 1859 bone disease 241, 624, 1485, 1499, 1978, 1983 bone edema 1371 bone erosion 716, 881, 1499, 1610 bone geometry 960 bone marrow 137, 183, 630, 713, 1085, 2158 bone marrow edema 135, 1963 bone marrow lesion 122, 131, 709 bone marrow macrophages 2158 bone metabolism 548, 957, 965, 973, 981, 1467, 1813, 2078, 2161 bone mineral density 994, 2157 bone morphogenetic proteins 610, 1468, 1487, 1980 bone resorption 1978 bone turnover 134, 1953 bone turnover markers 943, 2157 bony enlargements 185 botulinum toxin 114 brain activity 2097 brain magnetic resonance imaging 1162 breast cancer 912 bronchiectasis 1648 Btk 286 burden 204 BXD2 1412 C reactive protein 326, 491, 1000, 1077, 1804 C1q 1184 C4 498 C5a receptor antagonist 2032 C5aR 847 C6-deficient mice 1361 CACP 261 cadherin 602 cadherin-11 603, 1388 caffeine 1362 calcification 1978 calcineurin 2126 calcinosis 728, 1486, 1686 calcitonin 1500 calcium regulation 2179 calibrators 2251 calprotectin 537 CAM provider 1575 camk2 1503 camptodactyly arthropathy coxa vara pericarditis 261 canakinumab 894, 900 cancer 468 cancer treatments 977 candidate gene 92, 1592 cannabinoid 615, 841 capillaroscopy 11, 1236, 1615 capillary microscopy 1615 CAPS 2228 C carboxypeptidase B 1386 cardiovascular disease 67, 86, 90, 148, 309, 385, 389, 456, 461, 470, 479, 483, 485, 519, 531, 534, 554, 581, 582, 590, 628, 643, 771, 784, 793, 832, 870, 961, 1016, 1019, 1021, 1026, 1029, 1030, 1034, 1039, 1041, 1049, 1052, 1054, 1064, 1067, 1109, 1142, 1148, 1168, 1169, 1177, 1200, 1286, 1627, 1742, 1772, 1846, 1861, 1879, 2088, 2120, 2122, 2163, 2167, 2209, 2211, 2259 cardiovascular markers 375 cardiovascular risk 871, 1016, 1026 cardiovascular risk factors 542, 584 carotid plaque area 455 carotid ultrasound 2163 carpal tunnel 1567 carpal tunnel syndrome 1626 CARRA 1677 cartilage 122, 183, 192, 193, 215, 840, 875, 885, 1369, 1380, 1466, 1468, 1475, 1476, 1480, 1483, 1485, 1494, 1503, 1669, 1722, 2151 cartilage damage 1373, 2256 cartilage erosion 1388 cartilage loss 706 cartilage turnover 134, 1953 cartilage volume 938 case ascertainment 2093 case control study 2213 case-control 64 catabolism 1494 catenin 1503 caveolin-1 622 CAVI 1839 CCL4 503 CCP 2118 CCR7 1506 CD T cells 1242, 1248, 1253, 1268 CD138 1186 CD154 1243, 1244, 1245 CD226 1987 CD28 1505 CD3 830 CD3+ CD4- CD8- double negative T cell 434 CD36 2254 CD40L 267, 1243, 1244, 1245 CD70 1273 CD80 1505 CD86 1505 CDAI 73 celecoxib 151, 937 cell biology 634, 848, 860, 863, 1262, 1500, 1971, 1976 cell death 490, 1262 cell fusion 842 cell proliferation 505, 1262 abstract KEYWORD INDEX 2010 Program Book 359
- Page 1 and 2:
program B O O K Pre-Conference Cour
- Page 3 and 4:
program B O O K ABOUT ACR/ARHP EDUC
- Page 5 and 6:
TABLE OF CONTENTS ACCREDITATION . .
- Page 7 and 8:
TABLE OF CONTENTS ACR/ARHP Poster S
- Page 9 and 10:
TABLE OF CONTENTS Systemic Sclerosi
- Page 11 and 12:
the written consent of the ACR is p
- Page 13 and 14:
Shuttle Bus Service See shuttle sig
- Page 15 and 16:
ACR Resource Center Hours: Sunday,
- Page 17 and 18:
ACR Hotels + Map Complimentary shut
- Page 19 and 20:
to the premier meeting in rheumatol
- Page 21 and 22:
ACR Clinical Research Conference c/
- Page 23 and 24:
4:20 PM Germinal Center Reactions A
- Page 25 and 26:
3:30 PM Live Demonstration: Ultraso
- Page 27 and 28:
Upon completion of this session, pa
- Page 29 and 30:
MONDAY, NOVEMBER 8, 2010 ACR/ARHP R
- Page 31 and 32:
B301 Dermatological Manifestations
- Page 33 and 34:
Session Overview: The innate immune
- Page 35 and 36:
Upon completion of this session, pa
- Page 37 and 38:
B308 Inflammatory Eye Disease P/C M
- Page 39 and 40:
and insufficiency • recall source
- Page 41 and 42:
Session Overview: The advent of bio
- Page 43 and 44:
2:45 pm 641. Major Improvements in
- Page 45 and 46:
5 University of Twente and Medisch
- Page 47 and 48:
ACR/ARHP Combined Abstract Session
- Page 49 and 50:
REF 25th Anniversary Celebration 2:
- Page 51 and 52:
5:45 PM 699. Defining Latent and/or
- Page 53 and 54:
Lilian H. D. van Tuyl 8 , Karin Bri
- Page 55 and 56:
ACR REF Special Sessions 4:30 - 6:0
- Page 57 and 58:
REF 5K Run/Walk 6:00 - 8:00 am See
- Page 59 and 60:
• discuss the principles of early
- Page 61 and 62:
ACR Medical Aspects of Rheumatic Di
- Page 63 and 64:
10:00 am 1349. Work as a Daily Chal
- Page 65 and 66:
ACR Plenary Session II: Discovery 2
- Page 67 and 68:
B210 B301 Pediatrics: Periodic Feve
- Page 69 and 70:
Session Overview: As a clinical edu
- Page 71 and 72:
Thomas J. Murphy Ballroom Giant Cel
- Page 73 and 74:
3:45 PM 1367. Serum Urate Levels in
- Page 75 and 76:
A411 Rheumatoid Arthritis - Human E
- Page 77 and 78:
2:45 PM 1405. Development of a Visi
- Page 79 and 80:
4:30 PM Anti-citrullinated Protein
- Page 81 and 82:
of Experimental Orthopedics, Univer
- Page 83 and 84:
5:30 PM 1438. Mortality/Morbidity i
- Page 85 and 86:
5:30 PM 1456. Belimumab, a BLyS-Spe
- Page 87 and 88:
Develly 5 , Bernardo L. F. Fernande
- Page 89 and 90:
7:30 PM Role of IL-1 in Human Artic
- Page 91 and 92:
• compare the prevalence and epid
- Page 93 and 94:
6:45 PM Macrophage Activation Syndr
- Page 95 and 96:
Upon completion of this session, pa
- Page 97 and 98:
Session Overview: This roundtable d
- Page 99 and 100:
B303 Scleroderma: Systemic Sclerosi
- Page 101 and 102:
9:00 - 10:30 am - Poster Hall Morni
- Page 103 and 104:
• describe the role of IL-1 and I
- Page 105 and 106:
Session Overview: For the clinician
- Page 107 and 108:
• identify the aspects for day-to
- Page 109 and 110:
ACR Study Groups 1:00 - 2:00 PM B30
- Page 111 and 112:
Session Overview: Ultrasound and ma
- Page 113 and 114:
Session Overview: Fifty percent of
- Page 115 and 116:
1:20 PM Academic Rheumatology Seth
- Page 117 and 118:
ACR Concurrent Abstract Sessions 2:
- Page 119 and 120:
3:00 PM 2110. Rheumatologists on th
- Page 121 and 122:
2:45 PM 2133. Reasons for Decline i
- Page 123 and 124:
Session Overview: We are witnessing
- Page 125 and 126:
Session Overview: Systemic sclerosi
- Page 127 and 128:
Oaks, CA, 2 Amgen Inc., San Francis
- Page 129 and 130:
5:00 PM 2176. A Role of Autoimmune
- Page 131 and 132:
4:30 PM 2198. Association between V
- Page 133 and 134:
ARHP Concurrent Sessions 4:30 - 6:0
- Page 135 and 136:
THURSDAY, NOVEMBER 11, 2010 ACR/ARH
- Page 137 and 138:
• apply these basic statistics to
- Page 139 and 140:
9:15 AM The ACR/EULAR Definition of
- Page 141 and 142:
Immunology, Oslo University Hospita
- Page 143 and 144:
9:15 AM 2239. Factors Associated wi
- Page 145 and 146:
Upon completion of this session, pa
- Page 147 and 148:
Mikkel Østergaard 6 , Paul Emery 4
- Page 149 and 150:
Ende 4 , 1 Department of Rheumatolo
- Page 151 and 152:
ACR Poster Session A Cytokines, Med
- Page 153 and 154:
ACR Poster Session A 51. Associatio
- Page 155 and 156:
ACR Poster Session A 83. Respirator
- Page 157 and 158:
ACR Poster Session A 121. Bone Dens
- Page 159 and 160:
ACR Poster Session A 142. The Intra
- Page 161 and 162:
ACR Poster Session A 171. Early Pro
- Page 163 and 164:
ACR Poster Session A Pediatric Rheu
- Page 165 and 166:
ACR Poster Session A 233. Prevalenc
- Page 167 and 168:
ACR Poster Session A 266. Subtype S
- Page 169 and 170:
ACR Poster Session A 297. Body Weig
- Page 171 and 172:
ACR Poster Session A 325. Patient R
- Page 173 and 174:
ACR Poster Session A 356. Influence
- Page 175 and 176:
ACR Poster Session A 383. Efficacy
- Page 177 and 178:
ACR Poster Session A 409. Rituximab
- Page 179 and 180:
ACR Poster Session A 441. Recombina
- Page 181 and 182:
ACR Poster Session A 465. Immunoglo
- Page 183 and 184:
ACR Poster Session A 496. IRF8 Alle
- Page 185 and 186:
ACR Poster Session A 521. DC-STAMP
- Page 187 and 188:
ACR Poster Session A 546. Prevalenc
- Page 189 and 190:
ACR Poster Session A 571. Epidemiol
- Page 191 and 192:
ACR Poster Session A 599. Validatio
- Page 193 and 194:
ACR/ARHP Poster Session B Halls B1
- Page 195 and 196:
ACR Poster Session B 767. Economic
- Page 197 and 198:
ACR/ARHP Poster Session B 792. The
- Page 199 and 200:
ACR/ARHP Poster Session B Universit
- Page 201 and 202:
ACR/ARHP Poster Session B 848. Cell
- Page 203 and 204:
ACR/ARHP Poster Session B 886. Scre
- Page 205 and 206:
ACR/ARHP Poster Session B 909. Regu
- Page 207 and 208:
ACR/ARHP Poster Session B 935. The
- Page 209 and 210:
ACR/ARHP Poster Session B 967. Frac
- Page 211 and 212:
ACR Poster Session B 993. Early Exp
- Page 213 and 214:
ACR/ARHP Poster Session B 1022. Com
- Page 215 and 216:
ACR/ARHP Poster Session B 1055. Son
- Page 217 and 218:
ACR Poster Session B 1084. Gene Exp
- Page 219 and 220:
ACR/ARHP Poster Session B 1111. Inc
- Page 221 and 222:
ACR Poster Session B hiroshima Memo
- Page 223 and 224:
ACR/ARHP Poster Session B 1166. Pre
- Page 225 and 226:
ACR/ARHP Poster Session B 1199. Typ
- Page 227 and 228:
ACR/ARHP Poster Session B 1225. Phy
- Page 229 and 230:
ACR/ARHP Poster Session B 1262. Lat
- Page 231 and 232:
ACR/ARHP Poster Session B 1294. End
- Page 233 and 234:
ACR/ARHP Poster Session B 1321. Cha
- Page 235 and 236:
ACR/ARHP Poster Session C Halls B1
- Page 237 and 238:
ACR/ARHP Poster Session C 1495. S10
- Page 239 and 240:
ACR/ARHP Poster Session C 1524. Inc
- Page 241 and 242:
ACR/ARHP Poster Session C 1555. Pro
- Page 243 and 244:
ACR/ARHP Poster Session C 1583. Ass
- Page 245 and 246:
ACR/ARHP Poster Session C 1596. Gen
- Page 247 and 248:
ACR/ARHP Poster Session C 1622. Flu
- Page 249 and 250:
ACR/ARHP Poster Session C Miscellan
- Page 251 and 252:
ACR/ARHP Poster Session C L. Woodwa
- Page 253 and 254:
ACR/ARHP Poster Session C 1692. Res
- Page 255 and 256:
ACR/ARHP Poster Session C 1719. Los
- Page 257 and 258:
ACR/ARHP Poster Session C 1749. Con
- Page 259 and 260:
ACR/ARHP Poster Session C 1780. Tow
- Page 261 and 262:
ACR/ARHP Poster Session C 1804. Eff
- Page 263 and 264:
ACR/ARHP Poster Session C Immunolog
- Page 265 and 266:
ACR/ARHP Poster Session C 2 Departm
- Page 267 and 268:
ACR/ARHP Poster Session C CA, 29 Un
- Page 269 and 270:
ACR/ARHP Poster Session C 1900. IL-
- Page 271 and 272:
ACR/ARHP Poster Session C 1930. Cor
- Page 273 and 274:
ACR/ARHP Poster Session C 1958. The
- Page 275 and 276:
ACR/ARHP Poster Session C 1988. Cha
- Page 277 and 278:
ACR/ARHP Poster Session C 2015. CpG
- Page 279 and 280:
ACR/ARHP Poster Session C 2038. Pri
- Page 281 and 282:
ACR/ARHP Poster Session C 2070. Ass
- Page 283 and 284:
REF Industry Roundtable-supported S
- Page 285 and 286:
REF Industry Roundtable-supported S
- Page 287 and 288:
INDUSTRY-SUPPORTED POST-CONFERENCE
- Page 289 and 290:
2010 ACR/ARHP Annual Meeting Leader
- Page 291 and 292:
2010 ACR/ARHP Annual Meeting Leader
- Page 293 and 294:
FLOOR PLANS 2010 Program Book 291
- Page 295 and 296:
VISIT THE EXHIBIT HALL New and inno
- Page 297 and 298:
EXHIBITORS La Lettre Du Rhumatologu
- Page 299 and 300:
ACKNOWLEDGEMENTS The ACR, the ARHP
- Page 301 and 302:
ACR/ARHP/REF STAFF LISTING Administ
- Page 303 and 304:
A Ahmed, Rafi, PhD T cell Memory .
- Page 305 and 306:
Cooper, Max D, MD Introduction . .
- Page 307 and 308:
Gerlag, Danielle Marie, MD, PhD The
- Page 309 and 310: Physical Examination Skills for Imp
- Page 311 and 312: Meroni, Pierluigi, MD Autoantibodie
- Page 313 and 314: Rogers, Joan C, PhD, OTR/ L Underst
- Page 315 and 316: Terkeltaub, Robert, MD Crystallizin
- Page 317 and 318: A Aarden, L 1825 Aarrass, S 1519, 1
- Page 319 and 320: Bakker, AAB 1095 Barendregt, B 753
- Page 321 and 322: Boutin-Le Thi Huong, D 478 Bout-Tab
- Page 323 and 324: Chatham, WW 457, 1146, 1454, 1457,
- Page 325 and 326: Daudon, M 875 Daugas, E 2009 Davatc
- Page 327 and 328: Ehst, B 758 Eicher, JL 688 Eisen, S
- Page 329 and 330: Gabay, OH 1484 Gaber, T 630, 1418 G
- Page 331 and 332: Guan, M 965 Guañabens, N 975 Gudbj
- Page 333 and 334: Homme, CL 730 Honda, E 434 Hong, JY
- Page 335 and 336: Kambayashi, T 1354 Kamdar, AA 1160
- Page 337 and 338: Kuller, LH 71 Kumabe, M 1164 Kumaga
- Page 339 and 340: Looney, C 941 Looney, MR 609 Looney
- Page 341 and 342: McCarthy, GM 1109, 1306, 1426 McCau
- Page 343 and 344: Myouzen, K 1577 Mysiw, WJ 2096 Mysl
- Page 345 and 346: Pans, M 1834 Parra, ER 605, 887 Ped
- Page 347 and 348: Radka, S 1174 Radner, H 296, 1745 R
- Page 349 and 350: Sack, KE 1898 Sacli, SF 1312 Saddic
- Page 351 and 352: 1463, 2071, 2140, 2141 Singh, K 212
- Page 353 and 354: Takahata, M 1492 Takasaki, Y 1731 T
- Page 355 and 356: 636 van Dongen, CJJ 90 Van Doornum,
- Page 357 and 358: Witte, T 824, 1578, 1579, 2214 Witt
- Page 359: A α-galactosylceramide 505 A2A kno
- Page 363 and 364: cost-utility 759, 1539 couples 1324
- Page 365 and 366: fibroblast like synoviocyte 27 fibr
- Page 367 and 368: impact 1063, 1325 inactive disease
- Page 369 and 370: methylation 826, 1253, 1489 methylt
- Page 371 and 372: 233, 234, 240, 243, 252, 262, 268,
- Page 373 and 374: 1599, 1600, 1603, 1605, 1606, 1609,
- Page 375 and 376: 1226, 1227, 1229, 1230, 1231, 1233,
- Page 377 and 378: Abelson, Abby Goulder, MD Education
- Page 379 and 380: Massarotti, Elena M, MD Systemic Lu
- Page 381 and 382: ACR Annual Meeting fellowS-in-train
- Page 383 and 384: NOTES 2010 Program Book 381
- Page 385 and 386: Enbrel ® (etanercept) Brief Summar
- Page 387 and 388: Prescription Enbrel ® (etanercept)
Change language